Skip to NavigationSkip to content

News

0
AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra in asthma, and Lynparzain ovarian cancer.
0
Rumours of a $7billion Juno Therapeutics takeover by Celgene, accelerated approval in the US and Europe for Novartis' CAR T therapy Kymriah, and...
0
Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and has made another move to further...
0
UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the treatment of ROS1-positive...

Features

As industry discourse continues to discuss how real world evidence can be transformative for the regulatory landscape, Jacqueline Corrigan-Curay...